ArticleScientific reports2026
AQbD-assisted HPLC method for simultaneous determination of methylparaben and propylparaben in liquid oral dosage forms.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The determination of preservatives like methylparaben (MP) and propylparaben (PP) in pharmaceutical syrups is critical for quality control. Traditional one-factor-at-a-time (OFAT) method development often fails to account for interactions between variables, leading to less robust procedures. This study aims to develop and validate a robust HPLC method for the simultaneous determination of MP and PP using a systematic Analytical Quality by Design (AQbD) approach. An initial risk assessment (Ishikawa diagram and Failure Mode and Effects Analysis) identified five critical method attributes (CMAs): mobile phase type, organic phase percentage, pH, flow rate, and column temperature. These CMAs were systematically optimized using a D-optimal design (34 runs) with resolution, retention time, and tailing factor defined as critical quality attributes (CQAs). Statistical analysis revealed that organic solvent type and percentage were the most significant factors affecting resolution. The Method Operable Design Region (MODR) was established, and the optimal conditions were predicted as 40 °C, 1.5 mL/min flow rate, pH 6.1, and 67.7% methanol, achieving baseline separation within 6 min. The method was validated per ICH Q2(R2) guidelines, demonstrating excellent linearity (R² > 0.99 for both analytes), precision (%RSD < 2%), and accuracy (recovery 98.2-99.8%). The method was successfully applied to quantify MP and PP in commercial pharmaceutical syrups, with results falling within expected ranges. The AQbD approach ensured a robust, well-understood, and reliable method, suitable for routine quality control and capable of withstanding minor variations in chromatographic conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.